Better Health for All

No relevant evidence was found in the provided articles to assess Xeris Biopharma Holdings, Inc. against the 'Better Health for All' ethical value. The articles either contained no data due to a 404 error

or pertained to a different company in the hospitality industry.

Fair Pay & Worker Respect

For 2024, the CEO's annual total compensation was $3,827,109, and the median employee's annual total compensation was $214,795, resulting in a pay ratio of approximately 17.82:1.

The company offers comprehensive medical, dental, and vision insurance, as well as life, short-term, and long-term disability insurance. A former sales representative was placed on temporary, unpaid personal leave of absence starting November 29, 2021, after receiving a religious exemption to a mandatory COVID-19 vaccine policy. Her employment was terminated effective April 22, 2022, and she filed a charge of discrimination and retaliation with the EEOC in March 2022. The company offered a severance package in exchange for a signed release and withdrawal of her EEOC charge. A motion to dismiss her complaint was granted without prejudice, with leave to file an amended complaint by April 27, 2023.

Kind to Animals

XeriJect® suspensions have been tested in multiple animal models.

There is no information provided regarding the extent to which non-animal testing methods are employed for product safety and efficacy, or if alternative methods are used beyond legal mandates.

Planet-Friendly Business

The provided articles, primarily financial reports and product updates, do not contain specific, quantifiable data points for any of the 'Planet-Friendly Business' KPIs. While one article mentions that using internet proxy materials is believed to "help lower costs and reduce the environmental impact of printing annual meeting materials,"

this is a general statement of intent and does not provide measurable outcomes or specific data to score any KPI, such as a percentage reduction in packaging CO2 or total emissions. The Nominating and Corporate Governance Committee oversees the company's environmental, social, and governance efforts, but no specific outcomes or metrics are provided. Consequently, no KPIs can be scored based on the evidence provided.

Respect for Cultures & Communities

No relevant information or specific data points regarding Xeris Biopharma Holdings, Inc.'s respect for cultures and communities were found in the provided articles.

Both articles explicitly stated a lack of relevant data or that the requested page was not found, preventing any KPI assessment.

Safe & Smart Tech

Xeris Biopharma Holdings, Inc. has certified adherence to the EU-U.S. Data Privacy Framework and the Swiss-U.S. Data Privacy Framework Principles, with the policy last updated on May 1, 2024.

The company states it limits the collection of personal data to information relevant for processing and that personal information collected for a particular purpose will only be saved and used for that purpose. Users have the right to obtain confirmation, access, correct, amend, delete, and limit the use and disclosure of their personal data by contacting privacy@xerispharma.com. Xeris also states it complies with COPPA and maintains reasonable technical, administrative, and physical controls to secure personal information. There is no documented evidence of unauthorized data use incidents.

Zero Waste & Sustainable Products

No specific, concrete data points were found in the provided articles for any of the KPIs related to Zero Waste & Sustainable Products for Xeris Biopharma Holdings, Inc.

The articles primarily focus on financial performance, product development, general industry trends, or initiatives by other companies (e.g., MilliporeSigma, Cryopak, NexKemia), rather than XERS.US's direct waste management, product sustainability, or circular economy practices.